My Definition of Deviation
|
|
- Mary Butler
- 6 years ago
- Views:
Transcription
1 Development & Operation of a QA System for Deviations from SOPs in a Clinical Cell Therapy Laboratory PACT Webinar July 20, 2006 David H. McKenna, M.D. Clinical Cell Therapy Laboratory Molecular & Cellular Therapeutics University of Minnesota My Definition of Deviation True deviations, adverse reactions, complaints (per FDA), AND ALSO changes from SOPs and notable or noteworthy events.
2 Definitions Deviation: An event 1) that represents a deviation from applicable regulations in this part or from applicable standards or established specifications that relate to the prevention of communicable disease transmission or human cellular or tissue-based product (HCT/P) contamination; or 2) that is an unexpected or unforeseeable event that may relate to the transmission or potential transmission of a communicable disease or may lead to HCT/P contamination. Complaint: Any written, oral, or electronic communication about a distributed HCT/P that alleges: 1) that an HCT/P has transmitted or may have transmitted a communicable disease to the recipient of the HCT/P; or 2) any other problem with an HCT/P relating to the potential for transmission of communicable disease, such as the failure to comply with cgtp. Adverse reaction: A noxious and unintended response to any HCT/P for which there is a reasonable possibility that the HCT/P caused the response -Subpart A General Provisions (Sec ) Definitions (cont.) Notable/Noteworthy Event: An occurrence that may not fit into the previous definitions but still requires attention (medical, technical, etc.), as it may impact on patient and/or product outcome -In-house
3 Nuts and Bolts of a Deviation Management System Functions of the quality program must include: Investigating and documenting HCT/P deviations and trends of HCT/P deviations relating to core cgtp requirements... [Sec (b)(6)] Periodic review and analysis of all deviations, at least once a year (proposed GTPs) Reporting: You must report to FDA an adverse reaction involving a communicable disease if [Sec (a)] You must report HCT/P deviations (relating to the core cgtp requirements) related to a distributed HCT/P for which you performed a manufacturing step if deviation occurred in your facility or another facility under contract, agreement or arrangement [Sec (b)] Document Improve Deviation Management Investigate & Report Track & Trend Correct
4 Deviation Management System Tools Standardized Form User Friendly Database - Microsoft Access Graphs & Tables - Microsoft Access/Excel Reports
5 Why a deviation database? Flexible and powerful means of tracking deviations Identifying recurring and sentinel events Facilitates regulatory compliance Promotes continuous process improvement Deviation Database Design Easy to use Categorization of deviations Product/patient impact scoring Analysis and graphic display Report capabilities Pick-lists, description codes, clients, tech, equipment etc..
6
7
8 Additional Features Security-compliant with FDA regulations (21CFR11) Requires usernames/passwords Access limited to dedicated staff Secured from unauthorized users Reviewed by Operations Manager Audit trails Username, original & added data, date/time of entry Complete tracking of data from initiation to modification to deletion Daily virus scanning Backed-up on server; in fire-proof safe; off-site Nuts and Bolts of a Deviation Management System Functions of the quality program must include: Investigating and documenting HCT/P deviations and trends of HCT/P deviations relating to core cgtp requirements... [Sec (b)(6)] Periodic review and analysis of all deviations, at least once a year (proposed GTPs) Reporting: You must report to FDA an adverse reaction involving a communicable disease if [Sec (a)] You must report HCT/P deviations (relating to the core cgtp requirements) related to a distributed HCT/P for which you performed a manufacturing step if deviation occurred in your facility or another facility under contract, agreement or arrangement [Sec (b)]
9 Document & Investigate Complete deviation form Investigate in real time Determine if need for Corrective Action/Preventative Action (CAPA) Root Cause Analysis/Investigation Investigational Report Reasons for Root Cause Investigation Examples Moderate Severe Risk to Patient Outcome CD34 Selection Failure Cord Blood Product Mix-up Adverse Reactions Engraftment Failure QA System Failures Equipment Monitoring Failure Impact upon Multiple Products/Patients Defective Freezing Bag
10 Investigational Report Description Description of event Data, test results, documents Identification of members of the review committee Patient impact, outcome analysis Review Committee Identify root cause Determine if reportable and to whom Identify corrective plan Corrective Plan Define with timeline Implement Monitor Nuts and Bolts of a Deviation Management System Functions of the quality program must include: Investigating and documenting HCT/P deviations and trends of HCT/P deviations relating to core cgtp requirements... [Sec (b)(6)] Periodic review and analysis of all deviations, at least once a year (proposed GTPs) Reporting: You must report to FDA an adverse reaction involving a communicable disease if [Sec (a)] You must report HCT/P deviations (relating to the core cgtp requirements) related to a distributed HCT/P for which you performed a manufacturing step if deviation occurred in your facility or another facility under contract, agreement or arrangement [Sec (b)]
11 Review & Analysis Quarterly basis Collectively and for each client Formally track/trend by product type, category, patient/product impact, equipment, etc.. Present and discuss with each client
12
13 Nuts and Bolts of a Deviation Management System Functions of the quality program must include: Investigating and documenting HCT/P deviations and trends of HCT/P deviations relating to core cgtp requirements... [Sec (b)(6)] Periodic review and analysis of all deviations, at least once a year (proposed GTPs) Reporting: You must report to FDA an adverse reaction involving a communicable disease if [Sec (a)] You must report HCT/P deviations (relating to the core cgtp requirements) related to a distributed HCT/P for which you performed a manufacturing step if deviation occurred in your facility or another facility under contract, agreement or arrangement [Sec (b)]
14 Reporting Sec Focused on Product Contamination Transmission of communicable disease Failure of product function or integrity Final Thoughts Keep system practical, efficient, and dynamic Realize that deviations will occur Complexity of field & human nature Primary goal is quality improvement
15 Acknowledgements Diane Kadidlo Darin Sumstad Jeff McCullough McKenna D, Kadidlo D, Sumstad D, McCullough J. Development and operation of a quality assurance system for deviations from standard operating procedures in a clinical cell therapy laboratory. Cytotherapy 2003; 5(4):
Challenges In Cell Product Labeling, Tracking And Traceability
Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department
More informationQuality Management. Carlos Bachier, MD
Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory
More informationFDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)
FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach
More informationRegulatory Implications for Global Manufacturing Development of Regenerative Medicines
Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells
More informationHCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More information21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.
Pt. 820 device together with an explanation of the basis for the estimate; (iv) Information describing the applicant s clinical experience with the device since the HDE was initially approved. This information
More informationHCT/P Deviations & Reporting. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017
HCT/P Deviations & Reporting CASE STUDIES FROM TISSUE AND EYE BANKS AND CELLULAR THERAPY. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017 Tissue Bank Perspective Ashley
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationPART 820 QUALITY SYSTEM REGULATION. 21 CFR Ch. I ( Edition)
814.126 (b) Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More informationDISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND
REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare
More informationRecent FDA Inspection Findings and Trends
Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11
More informationPACT. PACT Program. Production Assistance for Cellular Therapies
PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert
More informationNetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration. Fourth Edition
NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration Fourth Edition INTERNATIONAL STANDARDS FOR CORD BLOOD COLLECTION, BANKING, AND RELEASE FOR ADMINISTRATION
More informationMedical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC
Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC - 2013 Quality Business Acceptance Activities 1 ..FDA Across the Globe.. 2 ..Warning Letters and FDA 483 update..
More information10-CBA providing access to unlicensed cord blood units
10-CBA providing access to unlicensed cord blood units Using the NMDP IND to access unlicensed cord blood units Amy Hays, Sr. Clinical Research Specialist, CIBMTR History of CBUs First CBU transplant done
More informationStandard Operating Procedures for HTA samples
Standard Operating Procedures for HTA Samples Page 1 of 16 Standard Operating Procedures for HTA samples NB the Standard Operating Procedures (SOPs) listed below define the physical laboratory processes
More informationQuality and Medical Devices: ISO 13485:2003
Quality and Medical Devices: ISO 13485:2003 Quality Management System requirements for Medical Devices manufacturers O3 Enterprise s.r.l. ISO 13485 Quality Management Systems Medical Device O3 Enterprise
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationINTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION FOR HEMATOPOIETIC CELLULAR THERAPIES
INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION FOR HEMATOPOIETIC CELLULAR THERAPIES Draft Sixth Edition April 2014 NOTICE These Standards are designed to
More informationAcademic and Industry Partnerships -The Next Generation-
Educational Web Seminar -The Next Generation- Thursday, June 8, 2017 12:00 noon 1:00 PM ET Diane Kadidlo, BS, MT(ASCP), SBB Facility Director Molecular and Cellular Therapeutics University of Minnesota
More informationINTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION
INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Seventh Edition DRAFT May 2017 NOTICE These Standards are designed to provide minimum guidelines
More informationAudit Program Background Definition Management Example Content Risk assessment approach
AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There
More informationAuditing Software Vendors
Auditing Software Vendors By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Auditing Software Vendors Copyright
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationDiscussion Paper on the Validation of Pharmacovigilance Software provided via SaaS
Discussion Paper on the Validation of Pharmacovigilance Software provided via SaaS June 2012 K Edmonds Page 1 of 10 Page 2 of 10 Contents 1. Introduction... 4 2. Quality Statement ISO 9001:2015... 4 3.
More informationQuality Manual. Index
This quality policy manual is for the use of, its Clients, Vendors, and the appropriate Regulatory Agencies. Unauthorized duplication or transfer to others is prohibited. Index Authorization... 3 Introduction...
More informationThe Clinical Research Regulatory Process
The Clinical Research Regulatory Process Understanding the Impact A CenterWatch-Complion Survey by Rick Arlow, Founder and CEO Complion Inc. Introduction The importance of data validity obtained from a
More informationFood and Drug Administration, HHS Pt Sec Scope Definitions Quality system.
Food and Drug Administration, HHS Pt. 820 authorized designee. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm
More informationOMPQ Update: Quality Systems and Drug Lifecycle Risk Management
OMPQ Update: Quality Systems and Drug Lifecycle Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing & Product Quality FDA/CDER/OC FDA Inspections Summit October 22, 2014
More informationRisk Based Approach To Complaint Handling
Risk Based Approach To Complaint Handling Khaudeja Bano, M.D. Senior Medical Director, Medical Device Safety Head, AbbVie Inc. Life Sciences Product Complaints Congress Europe Dublin, Ireland December
More informationRole of Industrial Engineer in Compliance with FDA Regulations
Role of Industrial Engineer in Compliance with FDA Regulations Wanda J. Torres Medical Device Specialist Libia M. Lugo Drug Specialist Simposio de Ingeniería Industrial Polytechnic University, San Juan
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationZOLL Document Number: 90E0004 Page 5 of 15 Maintenance of Quality Records
ZOLL Number: 90E0004 Page 5 of 15 1. INTRODUCTION 1.1 Purpose 1.2 Scope The purpose of this document is to provide guidance regarding the identification of a quality record and the documentation practices
More informationTo provide a framework and tools for planning, doing, checking and acting upon audits
Document Name: Prepared by: Quality & Risk Unit Description Audit Process The purpose of this policy is to develop and sustain a culture of best practice in audit through the use of a common framework
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationChapter 1. Pharmaceutical Industry Overview
Chapter 1 Pharmaceutical Industry Overview 1.1 Introduction 2 1.2 Regulations 2 1.2.1 Health Insurance Portability and Accountability Act 2 1.2.2 The Code of Federal Regulations 3 1.2.3 Guidance for Industry
More informationWindchill Quality Management
Windchill Quality Management Closed-Loop Quality for Medical Device Innovators Windchill Quality Management is purpose-built for medical device makers who seek to accelerate delivery of breakthrough medical
More informationIS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing Practice PHS Act: : Public Health Service Act CFR: : Code of Federal Regulations CP: : Comp
PREPARING FOR AN FDA INSPECTION August 11, 2011 Kip J. Hanks, Investigator Biologics National Expert FDA Division of Domestic Field Investigations 1 IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationRegulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective
Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective ASQ509 Biomed/Biotech SIG 2/1/18 Xiaobin Victor Lu Division of Cellular and Gene Therapies Office of Tissues
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationFDA Initiatives and Regulatory Trends for Life Sciences. Larry Spears President L. Spears Consulting
FDA Initiatives and Regulatory Trends for Life Sciences Larry Spears President L. Spears Consulting Before We Begin If you experience technical problems, please contact GoToMeeting Technical Support at
More informationEVENT TYPE TIMING REQUIRED FORM
Reportable Events EVENT TYPE TIMING REQUIRED FORM Unanticipated Problem or Adverse Event 10 days Event Reporting Form Death (related) 10 days Event Reporting Form Death (not related) Renewal Summary with
More information10 "Must-Haves" for the Life Sciences Learning Management System
10 "Must-Haves" for the Life Sciences Learning Management System Why the Life Sciences LMS Needs to Demonstrate Record Control UL talks to many Life Sciences companies that are exploring learning and development
More informationRisk-Based Monitoring Update Volume IV
Risk-Based Monitoring Update Volume IV 1. Introduction TransCelerate s Risk-Based Monitoring (RBM) initiative continues to produce tangible outputs during the first half of 2015. The purpose of RBM Update
More informationForce.com and the FDA CFR 21 Part 11 Requirements
Force.com and the FDA CFR 21 Part 11 Requirements Overview of Capabilities to Enable Compliance Version 4, Nov 14 Last Updated: November 10, 2014 Disclaimer This statement does not confer legal advice,
More informationSoftware Quality Regulatory Trends
Software Quality Regulatory Trends By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Software Quality Regulatory
More informationINTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION
INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Sixth Edition Version 6.1 NOTICE These Standards are designed to provide minimum guidelines
More informationRegulation of Microbiota- Based Products
Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal
More informationUDI Guidance Document for Medical Devices Containing HCT/P
LEARNING UDI COMMUNITY UDI Guidance Document for Medical Devices Containing HCT/P WWW.AHRMM.ORG / LUC INTRODUCTION: Human cells, tissues, or cellular or tissue-based products (HCT/Ps) are a precious resource
More informationFDA Quality Metrics Guidance
FDA Quality Metrics Guidance Marlène García Swider, Ph.D., CQM, CSSBB Institute of Validation Technology Quality Metrics Conference February 22 24, 2016 Coronado Island, San Diego, CA Personal Claim This
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationDOCUMENT REVISION HISTORY PAGE. 90C0010 X 2 of 20. Revision History Of Document
DOCUMENT REVISION HISTORY PAGE Document Number: Rev: Page: 90C0010 X 2 of 20 Title: Corrective and Preventive Action Rev Revision History Of Document CO Number Description of Change Author Effective Date
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationBuilding Your Best Internal Audit Team for Quality Results. FDA Inspections Summit. November 3, 2017 Presenter: Susan Schniepp
Building Your Best Internal Audit Team for Quality Results FDA Inspections Summit November 3, 2017 Presenter: Susan Schniepp Discussion Topics Regulatory Requirements Benefits of Internal Audits Elements
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationMitochondrial Manipulation Technologies: Preclinical Considerations
Mitochondrial Manipulation Technologies: Preclinical Considerations Wei Liang, Ph.D. FDA / CBER / OCTGT Wei.liang@fda.hhs.gov Ethical and Social Policy Considerations of Novel Techniques for Prevention
More informationImportance of the CAPA System
Passion for Quality Importance of the CAPA System PIA 06/20/2013 Pepe Rodríguez-Pérez, PhD Business Excellence Consulting Inc www.capapr.com...+ www.calidadpr.com Purpose and Importance of the CAPA System
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationHumantech Environmental Management System Manual
Humantech Management System Version 1.0 March 2014 Humantech, Inc. Humantech Management System Revision No.: 1 Date : 03-10-14 Prepared by: Approved by: (EMR) President Revision History Revision Date Description
More informationWorking with the global leaders in foodservice, we are leading the way in improving recipe management processes
OVERVIEW COMPREHENSIVE RECIPE INFORMATION PREPARATION, TRACEABILITY, NUTRITION, ALLERGEN & COSTINGS INFO AT YOUR FINGERTIPS Our client has requested we now provide nutritional information on our menus.
More informationGeneral Requirements for the Competence of Testing and Calibration Laboratories
ISO 17025:2005 POSITION PAPER General Requirements for the Competence of Testing and Calibration Laboratories EXECUTIVE SUMMARY This position paper provides a high-level overview of how LabVantage supports
More informationCARDIOVASCULAR DEVICE MANUFACTURER
CUSTOMER CASE STUDY CARDIOVASCULAR DEVICE MANUFACTURER Moving from Paper Processes to an Automated Enterprise Quality and Compliance System CARDIOVASCULAR DEVICE MANUFACTURER Moving from Paper Processes
More informationFAQ ABOUT. 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS
FAQ ABOUT 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS XYTEX INTERNATIONAL, LTD. AUGUSTA, GEORGIA NOVEMBER 2005 Xytex International, 2005 Xytex is a registered trademark of Xytex International,
More informationPharmacovigilance Playbook (Part 1 of 2)
PHARMACOVIGILANCE AND RISK MANAGEMENT Pharmacovigilance Playbook (Part 1 of 2) Compiled By: Dr. Mufti Suhail Sayeed James Lind Institute www.jliedu.com www.jli.edu.in James Lind Institute www.jliedu.com
More informationDrug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014
Drug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014 Copyright 2015 by FDAnews. All rights reserved. Photocopying or reproducing this report in any form, including electronic or facsimile
More informationISBT 128 Labeling Overview. Fran Rabe University of Minnesota Molecular and Cellular Therapeutics
ISBT 128 Labeling Overview Fran Rabe University of Minnesota Molecular and Cellular Therapeutics ICCBBA u Not for profit organization u Formally: International Council for Commonality in Blood Banking
More informationTECHNICAL REQUIREMENTS (CLAUSE 5)
LECTURE 4 THE ELEMENTS OF ISO/IEC 17025 - TECHNICAL REQUIREMENTS (CLAUSE 5) Slide 1 ISO 17025 - RELATIONSHIP OF EACH REQUIREMENTS Management System Organization Quality system Continual Improvement Management
More informationRegulatory Schema for Blood Transfusion Microbiotal transplant conference
Regulatory Schema for Blood Transfusion Microbiotal transplant conference Baltimore, 3-4 December 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine Medical Director, Transfusion
More informationLaboratory Internal Audit Plan MAY 2017
Laboratory Internal Audit Plan MAY 2017 Acknowledgements The following APHL workgroup members contributed to this document: Charlene Thomas, BS, MT(ASCP), manager, microbiologist, Alabama Bureau of Clinical
More informationReplacing Analytical Methods for Release and Stability Testing A Regulatory Perspective
Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh
More informationThe SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies
The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies By Rob Sims, UL Compliance to Performance When Life Sciences companies
More informationPharmacovigilance and the Generic Industry
Pharmacovigilance and the Generic Industry Presented by Joan Janulis, RAC Vice President Lachman Consultant Services Inc. 2015 Lachman Consultant Services, Inc. All rights reserved. Legal Notice The information
More informationDesign Qualification SOP
1.0 Commercial in Confidence 16-Aug-2006 1 of 13 Design Qualification SOP Document No: SOP_0400 Prepared by: David Brown Date: 16-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 16-Aug-2006 2 of 13
More informationData Integrity Issues in Today s Complex and Global Manufacturing Supply Chain: Regulatory Perspective
Data Integrity Issues in Today s Complex and Global Manufacturing Supply Chain: Regulatory Perspective Derek S. Smith, Ph.D. Office of Pharmaceutical Quality Office of Process and Facilities AAM FallTech
More informationReferences Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.
References Concept Principle a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 2, 2011 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville,
More informationMeasurement of Hematopoietic Stem Cell Potency Prior to Transplantation
WHITE PAPER Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation February, 2009 This White Paper is a forward-looking statement. It represents the present state of the art and future
More informationLeader in. prenatal. data management. LifeCycle version 3.2. Brochure not for distribution in the USA
Leader in prenatal data management LifeCycle version 3.2 Brochure not for distribution in the USA LifeCycle TM version 3.2 Why LifeCycle? Because you can be confident in the reported results LifeCycle
More informationBasic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D
Basic Good Laboratory Practice Christopher Jerome, B.Vet.Med., Ph.D Goals Outline the concept of Good Laboratory Practice (GLP) Provide some specific guidelines applicable to day to day work in the laboratory
More informationWHITE PAPER. Food Safety, From Farm to Fork. A Best-Practice Approach to Implementing a Food Safety Management System
WHITE PAPER Food Safety, From Farm to Fork A Best-Practice Approach to Implementing a Food Safety Management System Executive Summary Now, more than ever, all food chain stakeholders are required to demonstrate
More informationISO 14001:2015 Gap Analysis Check Sheet
? CONTEXT OF THE ORGANIZATION 4.1 Understanding the organization and its context The organization shall determine external and internal issues that are relevant to its purpose and that affect its ability
More informationSQF 2000 Guidance. Guidance for Food Sector Category 4 Fresh Produce Pack House Operations. 1st Edition
SQF 2000 for Food Sector Category 4 Fresh Produce Pack House Operations 1st Edition SEPTEMBER 2010 Safe Quality Food Institute 2345 Crystal Drive, Suite 800 Arlington, VA 22202 USA 202-220-0635 www.sqfi.com
More informationFDA Perspective on Plasma Quality and GMPs
FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California
More informationEXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER
EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER Disclaimer: This example is just one potential example of a vendor qualification form to verify the adequacy of the internal
More informationVanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
December 8, 2016 C2012 Web Seminar Series Identifying and Reporting Protocol Deviations Vanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
More informationOraSure simplementation of Quality Notifications in Compliance with FDA Regulations. Scott Baker, OraSure Technologies, Inc. Earl Haniford, QMS, Inc.
OraSure simplementation of Quality Notifications in Compliance with FDA Regulations Scott Baker, OraSure Technologies, Inc. Earl Haniford, QMS, Inc. LEARNING POINTS Review OraSure s Project Scope and Timeline
More informationOncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology
Oncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology Immunological Battle Ground Tumor immunity Tumor growth The tumor environment is an immunological battle ground:
More informationTampa Bay Information Network TBIN Audit Plan
TBIN Audit Plan Updated: 1 TBIN Audit Plan Table of Contents Introduction.3 Definitions & Acronyms....4 Documents...5 Purpose...6 Guidelines...6 Privacy.6 Client Consent...6 Privacy Notice 7 Removing TBIN
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM March 2015 HPFBI CANADA (HEALTH CANADA) Notice, Re: Regulatory Decision Summaries and Submissions Under Review Who s affected? Manufacturers of prescription drugs (pharmaceuticals and
More information